 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
RxSight, Inc. (RXST), an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. 
It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.
It primarily serves cataract doctors. Shares have formed a bullish "wedge" and higher share prices are expected.
On August 7th, RXST reported a loss of $0.40 per share on revenue of $20.81 million for the second quarter ended June 2023. The consensus estimate was a loss of $0.47 per share on revenue of $19.23 million. The company beat consensus estimates by 14.89% while revenue grew 83.19% on a year-over-year basis.
The company said it expects 2023 revenue of $81.0 million to $86.0 million. The company's previous guidance was revenue of $79.0 million to $84.0 million and the current consensus revenue estimate is $81.88 million for the year ending December 31, 2023.
Entry Point: $29.50
Stop Loss: $28.00
Trading Range: $9.78 to $33.77
Target Price: $32.50
